NK cell receptor NKG2C deletion and HLA-E variants are risk factors for severe COVID-19

doi:10.21203/rs.3.rs-34505/v1

PDF

Short Report

NK cell receptor NKG2C deletion and HLA-E variants are risk factors for severe COVID-19

https://doi.org/10.21203/rs.3.rs-34505/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 15 Jun, 2020

You are reading this latest preprint version

Patients infected with SARS-CoV-2 may show mild infection or may develop severe coronavirus disease 2019 (COVID-19). In the present study, we investigated whether there is an association between the severity of COVID-19 and the naturally occurring human genetic variants in the natural killer (NK) cell NKG2C receptor (NKG2C^wt/del) and its cellular ligand HLA-E (HLA-E*0101/0103). Both factors are essential components of the NKG2C⁺ NK cell response and important parts of the defence against pulmonary viral infection. NKG2C^del and HLA-E*0101 were significantly overrepresented in hospitalized patients (p=0.0006 and p=0.01, respectively) and particularly in critically ill patients requiring intensive care (p<0.0001 and p=0.01, respectively), compared to patients with mild symptoms or healthy controls. Both genetic variants were found to be independent risk factors for severe COVID-19. The data highlight that specific NKG2C⁺ NK cell responses play an important role against SARS-CoV-2 and that variations thereof may significantly influence the severity of disease.

Virology

Immunology

NKG2C

HLA-E

genetic variants

Patients infected with SARS-CoV–2 may either show mild or even asymptomatic infection or they may develop severe and potentially lethal coronavirus disease 2019 (COVID–19). So far, several risk factors for severe COVID–19 have been reported, including older age, male gender and co-morbidities, such as diabetes, cardiovascular or respiratory system diseases 1. However, these factors alone do not explain the differences in severity of COVID–19 observed between the individuals.

Antiviral host immune responses limit viral infections and influence the severity of viral diseases. Among these, natural killer (NK) cell responses are of major importance and significantly contribute to the early defense against pulmonary virus infections. NK cell activation depends on a panel of germline-encoded activating or inhibitory receptors. NKG2C+ cells are characterized by the elevated expression of the activating CD94/NKG2C receptor 2 and, in response to viral pulmonary infections, a subset of these highly potent NKG2C+ NK cells migrates into the lung 3. The interaction of NKG2C/CD94 and its cellular ligand HLA-E further mediates cytotoxic NK cell responses and the release of pro-inflammatory effector molecules of NKG2C+ cells against virus-infected cells 4.

The activation of NKG2C+ NK-cells varies depending on the presence of different genetic variants of the NKG2C receptor and of HLA-E, which naturally occur in the human population. Homozygous and heterozygous deletion of the NKG2C receptor was recently linked to decreased or absent NKG2C receptor expression 5 and was associated with the severity of specific virus infections 6. HLA-E occurs in European populations mostly as HLA-E*0101 or HLA- E*0103, which exhibit significant differences in cell surface expression levels and peptide binding capacities 7.

In the present study, we therefore investigated whether NKG2C deletion and specific HLA-E variants are significant factors associated with the severity of COVID–19 in the individual host.

Genotyping

Genomic DNA was isolated from respiratory swabs of COVID–19 patients and plasma of controls using NucliSens EasyMag extractor (BioMérieux, Marcy-l’Étoile, France). DNA was eluted in 50μl of nuclease- free H₂O. HLA-E*0101/0103 genotypes were determined by a Taqman assay and NKG2C^wt/del variants were determined by touchdown PCR as described before ^6,11.

Statistical analysis:

The distribution of the patient’s gender, genetic variants and donor and recipient serostatus was compared by the χ² - Test. For multiple comparisons, unpaired ANOVA and the Dunn’s post-test were used. For multivariable analysis a general log-linear model with genetic variables, gender and age groups (<60, 60–70, 70–80, >80 years) was used to identify combined genetic variables associated with the risk for severe SARS-CoV–2 infections, which were hospitalized or hospitalized in an ICU. P-values<0.05 were considered significant. Statistical analyses were performed using IBM SPSS Statistics 24. The study was approved by the local ethics committee (EK No. 1389/2019).

Characteristics of the Study Cohort

We included a total of 361 patients (median age: 69 years, 45% female), who were confirmed positive for SARS-CoV–2 by PCR from respiratory swabs 8 between the 17th February and 17th April 2020 at the Center of Virology, Medical University of Vienna. A total of 92/361 (25.5%) patients showed only minor symptoms and stayed in home quarantine (‘non-hospitalized’), 190/361 (52.6%) patients were hospitalized with severe COVID–19 symptoms but never required intensive care (‘hospitalized, non-ICU’), and 79/361 (21.9%) patients were severely affected and needed intensive care as defined earlier 9 (‘hospitalized-ICU’). In addition, we included 100 healthy control individuals (median age: 63 years, 50% female), from whom plasma samples were obtained at the Center for Virology between 2014–2016.

Patient characteristics are presented in Table 1. As shown, COVID–19 patients requiring ICU treatment were significantly older and were more likely to be males compared to non- hospitalized and hospitalized COVID–19 patients. This confirms previous data that male gender and higher age are risk factors for severe COVID–19 1.

Association between NKG2C and HLA-E genetic variants and severe COVID–19

From SARS-CoV–2 infected patients and controls, NKG2Cwt/del variants were determined by touchdown-PCR as described before 6. Overall, 65% of control persons encoded for the NKG2Cwt/wt variant, 33% for the NKG2Cwt/del and 2% for the NKG2Cdel/del variant. This is consistent with the NKG2C variant distribution in previously published European cohorts 10.

Among the COVID–19 patients in this study, hospitalized patients and patients requiring intensive care showed a significantly lower frequency of the NKG2Cwt/wt variant compared to non-hospitalized COVID–19 patients and controls (Fig.1A). Presence of the NKG2Cdel allele was significantly associated with severe COVID–19 requiring hospitalization and with hospitalization at ICU (p = 0.0006 and p<0.0001, respectively, χ2-Test).

We further analyzed the patients’ HLA-E*0101/0103 variants by a recently published Taqman assay 11. Overall, 33% and 35% of the controls were homozygous for the HLA-E*0101/0101 and HLA-E*0103/0103, respectively, while 32% showed the heterozygous HLA-E*0101/0103 variant. This distribution is similar to that shown in another European study cohort 11. In Fig.1B, the distribution of the HLA-E variant between controls and the different patient groups is shown. Hospitalized and ICU patients more often carried the HLA-E*0101/0101 and HLA- E*0101/0103 variants, compared to patients with mild COVID–19. The presence of an HLA- E*0101 allele was significantly associated with hospitalization and hospitalization in ICU (both: p = 0.01, χ2-Test).

We then analysed the association between combined HLA-E and NKG2C variants and COVID-19 severity. As shown in Figure 1C, the presence of combined NKG2Cwt/wt and HLA- E*0103/0103 alleles was significantly underrepresented in the hospitalized and ICU COVID–19 patients, and the combination of the hetero- and homozygous NKG2Cdel and HLA-E*0101 variants was associated with a higher risk for severe COVID–19 (both: p<0.0001, χ2-Test). We further performed a multi-variable analysis including the presence of the individual NKG2C alleles, HLA-E alleles, as well as age and gender of the different patient groups. Age >60 years (p>0.001 and p = 0.001, respectively), NKG2Cdel (p = 0.001 and p>0.001, respectively) and HLA- E*0101 (p = 0.006 and p = 0.006, respectively) alleles contributed significantly and independently to the overall probability for hospitalization without and with intensive care treatment.

Our data provide first evidence that NKG2C/CD94-driven NK cell response might be a main factor limiting virus infection and severity of COVID–19. We demonstrate that distinct naturally occurring genetic variants in the pathway leading to activation of NKG2C+ cells via the NKG2C/CD94/HLA-E axis may be of high importance for antiviral defence. Limited data are so far available concerning the NK cell response against SARS-CoV–2. Recently it was shown that NK cell counts were significantly reduced in patients with severe compared to those with mild COVID–19, respectively 12. In addition, NK cells from patients with severe COVID–19 showed increased expression of the inhibitory NKG2A+ receptor 12, which is associated with functional exhaustion of NK cells. Our data, linking the deletion of the activating NKG2C receptor with severe COVID–19, further underline the important role of a potent antiviral NK-cell response against SARS-CoV–2, and highlight that the NKG2C+ mediated NK cell response may significantly contribute to limit SARS-CoV–2 infections and to prevent severe COVID–19.

Epithelial cells of the respiratory tract are main targets of viral entry due to their high-level expression of the cellular ACE2 receptor 13. These cells also show elevated expression of HLA- E on their cell surface and are therefore targets of the NKG2C response 14. It is thus reasonable that the NKG2C-mediated NK-cell responses represent an important mechanism of immune defence against SARS-CoV–2 infected cells in the respiratory tract.

Furthermore, recently published in vitro studies demonstrated that cell surface expression levels are lower for HLA-E*0101/0101 than for HLA-E*0103/0103 7, which may result in a delayed or decreased NKG2C+ NK-cell response. Therefore both, deletion of the NKG2C receptor and HLA-E*0101 expression, may provide a disadvantage in antiviral defence.

Further studies are needed to elucidate in detail the impact of the NKG2C+ NK-cell-mediated immune responses on the course of COVID–19, also in relation to the role of inhibitory NK cell receptors and NK cell exhaustion. Revealing these NK cell driven antiviral mechanisms could be important for the development of new therapeutic options against COVID–19.

Disclosure of Conflicts of Interest

The authors declare that there is no conflict of interest. The project was founded by the Center for Virology, Medical University of Vienna.

Statement of ethics approval: The study was approved by the ethics committee of the Medical University of Vienna (EK No. 1389/2019). Human samples were obtained from past routine laboratory diagnosis and are stored frozen at the biobank of the Center for Virology, Medical University of Vienna. The patient’s consent was waived by the approving ethics committee.

Yang, J. et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. International Journal of Infectious Diseases 94, 91-95 (2020).
Guma, M. et al. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104, 3664-71 (2004).
Calabrese, D.R., Lanier, L.L. & Greenland, J.R. Natural killer cells in lung Thorax 74, 397-404 (2019).
Hervier, B., Russick, J., Cremer, I. & Vieillard, V. NK Cells in the Human Lungs. Front Immunol 10, 1263 (2019).
Goodier, M.R. et al. Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood 124, 2213-22 (2014).
Vietzen, H., Pollak, K., Honsig, C., Jaksch, P. & Puchhammer-Stockl, E. NKG2C Deletion Is a Risk Factor for Human Cytomegalovirus Viremia and Disease After Lung Transplantation. J Infect Dis 217, 802-806 (2018).
Rölle, A., Jäger, D. & Momburg, F. HLA-E Peptide Repertoire and Dimorphism—Centerpieces in the Adaptive NK Cell Puzzle? Frontiers in Immunology 9(2018).
Corman, V.M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 25, 2000045 (2020).
Phua, J. et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. The Lancet Respiratory Medicine 8, 506-517 (2020).
Redondo-Pachon, D. et al. Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. J Immunol 198, 94-101 (2017).
Paquay, M.M., Schellekens, J. & Tilanus, M.G. A high-throughput Taqman approach for the discrimination of HLA-E alleles. Tissue Antigens 74, 514-9 (2009).
Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17, 533-535 (2020).
Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nature Medicine (2020).
Jordier, F. et al. HLA-H: Transcriptional Activity and HLA-E Mobilization. Frontiers in Immunology 10(2020).

Table 1: Characteristics of the study cohort

Non- hospitalized N=92

Hospitalized (non-ICU) N=190

Hospitalized (ICU) N=79

p-value1

Female gender (%)

N=54 (58%)

N=78 (41%)

N=31 (39%)

P= 0.02

Non-Hospitalized vs Hospitalized: p=0.007 Non-Hospitalized vs ICU: p=0.01 Hospitalized vs ICU: p=0.79

Median Age (years, min-max)

45 (18-93)

74.4 (18-99)

78.3 (20-97)

P< 0.0001

Non-Hospitalized vs Hospitalized: P< 0.0001 Non-Hospitalized vs ICU: P< 0.0001 Hospitalized vs ICU: P< 0.0001

Abbreviations: ICU: Intensive Care Unit,

1 Differences were assessed with the χ² (gender) and ANOVA and Dunn’s post-test (age)

PDF

Version 1

posted 15 Jun, 2020

You are reading this latest preprint version

NK cell receptor NKG2C deletion and HLA-E variants are risk factors for severe COVID-19

Status:

Version 1

Abstract

Figures

Introduction

Material And Methods

Genotyping

Results

Characteristics of the Study Cohort

Association between NKG2C and HLA-E genetic variants and severe COVID–19

Discusssion

Declarations

References

Table

Status:

Version 1